You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tafasitamab

Showing 1 - 25 of 29
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle Cell Lymphoma Trial in Miami, Houston (Zanubrutinib, Tafasitamab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Miami, Florida
  • +1 more
Aug 31, 2023

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Tafasitamab
  • +3 more
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 7, 2022

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)

Recruiting
  • Diffuse Large-cell B-cell Lymphoma
  • plamotamab
  • +2 more
  • Seattle, Washington
    Swedish Cancer Center
May 2, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)

Recruiting
  • Mantle Cell Lymphoma
  • MCL
  • Basking Ridge, New Jersey
  • +6 more
Mar 27, 2023

Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)

Not yet recruiting
  • Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jun 17, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)

Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biopsy
  • +10 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 9, 2023

Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)

Recruiting
  • Non Hodgkins Lymphoma
  • Diffuse Large B-cell Lymphoma
  • tafasitamab
  • +3 more
  • Aichi, Japan
  • +4 more
Jan 24, 2022

Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +9 more
Jul 13, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • DLBCL
  • Tafasitamab
  • +2 more
  • Brussels, Belgium
  • +14 more
Mar 3, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Diffuse Large B Cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Dallas, Texas
  • +29 more
Jan 20, 2023

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide

Completed
Has Results
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
Dec 10, 2021

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (tafasitamab, parsaclisib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +49 more
Sep 21, 2022

Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)

Recruiting
  • Relapsed/Refractory
  • Tafasitamab
  • +8 more
  • Santa Fe, California
    California Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022

Lymphoma, B-Cell Trial in Worldwide (CC-220, Polatuzumab vedotin, Rituximab)

Withdrawn
  • Lymphoma, B-Cell
  • Boston, Massachusetts
  • +26 more
Sep 28, 2021

Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Rituximab (RTX)
  • +2 more
  • Anaheim, California
  • +157 more
Aug 1, 2022